

Table 6.6g
Immunosuppression Use for Maintenance Between Discharge
and One Year Following Transplantation, 1998 to 2007
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	88	139	134	168	181	160	183	199	173	208
Tx with Follow-up Immunosuppression Info	63	109	96	122	141	115	137	148	125	151
Corticosteroids										
Any in Category	100.0%	100.0%	96.9%	92.6%	86.5%	56.5%	58.4%	54.7%	59.2%	59.6%
Steroids	100.0%	100.0%	96.9%	92.6%	86.5%	56.5%	58.4%	54.7%	59.2%	59.6%
Cyclosporine										
Any in Category	19.0%	8.3%	8.3%	5.7%	8.5%	7.0%	3.6%	2.7%	2.4%	4.0%
Sandimmune	0.0%	0.0%	2.1%	0.0%	0.0%	0.0%	0.0%	1.4%	0.8%	0.7%
Neoral	19.0%	8.3%	5.2%	5.7%	6.4%	6.1%	3.6%	1.4%	1.6%	3.3%
Gengraf	0.0%	0.0%	1.0%	0.0%	1.4%	0.9%	0.0%	0.0%	0.0%	0.0%
Eon	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%
Tacrolimus										
Any in Category	96.8%	96.3%	95.8%	98.4%	95.0%	84.3%	85.4%	97.3%	98.4%	95.4%
Tacrolimus	96.8%	96.3%	95.8%	98.4%	95.0%	84.3%	85.4%	97.3%	97.6%	95.4%
Everolimus	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.0%
Antimetabolites										
Any in Category	93.7%	93.6%	81.3%	73.8%	63.8%	60.0%	60.6%	64.2%	60.8%	62.9%
Mycophenolate Mofetil	81.0%	91.7%	76.0%	70.5%	63.8%	59.1%	54.7%	56.1%	52.8%	52.3%
Mycophenolate Sodium	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.7%	6.4%	6.6%
Azathioprine	12.7%	1.8%	5.2%	3.3%	0.0%	0.9%	5.8%	3.4%	1.6%	4.0%
mTOR Inhibitors										
Any in Category	0.0%	17.4%	27.1%	16.4%	33.3%	24.3%	26.3%	27.7%	28.8%	23.8%
Sirolimus	0.0%	17.4%	27.1%	16.4%	33.3%	24.3%	26.3%	27.7%	28.8%	23.8%
Everolimus	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation. Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.